XERS
Xeris Biopharma Holdings, Inc.
Price Chart
Latest Quote
$7.36
Current Price| Previous Close | $7.36 |
| Open | $7.27 |
| Day High | $7.59 |
| Day Low | $7.22 |
| Volume | 1,472,530 |
Stock Information
| Shares Outstanding | 165.92M |
| Total Debt | $257.65M |
| Cash Equivalents | $91.60M |
| Revenue | $266.14M |
| Net Income | $-15.64M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.22B |
| EPS (TTM) | $-0.10 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 17/42| Debt to Equity | -9.17 |
| Debt to Earnings | 1.63 |
| Current Ratio | 1.67 |
| Quick Ratio | 1.12 |
| Avg Revenue Growth | 77.37% |
| Profit Margin | -27.00% |
| Return on Equity | 185.16% |
| Avg FCF Growth | -15.21% |
| FCF Yield | -3.10% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $7.36 | 1,550,000 |
| 2026-01-30 | $7.36 | 1,491,200 |
| 2026-01-29 | $7.24 | 1,318,500 |
| 2026-01-28 | $7.16 | 1,644,100 |
| 2026-01-27 | $7.51 | 1,291,700 |
| 2026-01-26 | $7.48 | 1,093,900 |
| 2026-01-23 | $7.44 | 1,669,000 |
| 2026-01-22 | $7.61 | 1,409,500 |
| 2026-01-21 | $7.62 | 1,462,100 |
| 2026-01-20 | $7.61 | 1,880,000 |
| 2026-01-16 | $7.52 | 1,618,700 |
| 2026-01-15 | $7.41 | 1,795,300 |
| 2026-01-14 | $7.58 | 1,283,700 |
| 2026-01-13 | $7.71 | 2,215,800 |
| 2026-01-12 | $7.87 | 1,582,200 |
| 2026-01-09 | $7.93 | 2,754,200 |
| 2026-01-08 | $8.13 | 4,956,200 |
| 2026-01-07 | $7.21 | 4,738,000 |
| 2026-01-06 | $6.96 | 2,296,300 |
| 2026-01-05 | $7.09 | 3,749,900 |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
📰 Latest News
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge?
Simply Wall St. • 2026-01-11T02:10:10Z
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns
Simply Wall St. • 2026-01-10T19:08:36Z
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents
Simply Wall St. • 2026-01-10T09:15:58Z
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
Motley Fool • 2026-01-01T00:09:57Z
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory
Insider Monkey • 2025-12-18T18:13:06Z
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed?
Simply Wall St. • 2025-12-06T09:09:45Z
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings
Simply Wall St. • 2025-12-03T16:10:53Z
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Simply Wall St. • 2025-11-09T12:29:21Z
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say
Zacks • 2025-11-06T14:30:04Z
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript
Motley Fool • 2025-11-06T14:16:35Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $35,050,000 | $26,328,000 | $20,809,000 | $11,989,000 |
| Cost Of Revenue | $36,832,000 | $28,645,000 | $22,634,000 | $13,318,000 |
| Total Revenue | $203,070,000 | $163,914,000 | $110,248,000 | $49,590,000 |
| Operating Revenue | $203,070,000 | $163,914,000 | $110,248,000 | $49,590,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $30,485,000 | $26,609,000 | $14,102,000 | $7,180,000 |
| Total Expenses | $236,716,000 | $207,924,000 | $192,188,000 | $164,746,000 |
| Other Income Expense | $1,706,000 | $2,364,000 | $-2,620,000 | $-702,000 |
| Net Non Operating Interest Income Expense | $-25,164,000 | $-21,858,000 | $-11,524,000 | $-6,867,000 |
| Total Other Finance Cost | $2,690,000 | - | - | - |
| Interest Expense Non Operating | $30,485,000 | $26,609,000 | $14,102,000 | $7,180,000 |
| Operating Expense | $199,884,000 | $179,279,000 | $169,554,000 | $151,428,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Net Interest Income | $-25,164,000 | $-21,858,000 | $-11,524,000 | $-6,867,000 |
| Interest Income | $5,321,000 | $4,751,000 | $2,578,000 | $313,000 |
| Normalized Income | $-56,474,243 | $-64,572,505 | $-92,078,829 | $-122,023,000 |
| Net Income From Continuing And Discontinued Operation | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Total Operating Income As Reported | $-33,646,000 | $-44,010,000 | $-81,940,000 | $-115,156,000 |
| Net Income Common Stockholders | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Net Income | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Net Income Including Noncontrolling Interests | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Net Income Continuous Operations | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Pretax Income | $-57,104,000 | $-63,504,000 | $-96,084,000 | $-122,725,000 |
| Special Income Charges | $1,698,000 | $2,363,000 | $-4,380,000 | $0 |
| Interest Income Non Operating | $5,321,000 | $4,751,000 | $2,578,000 | $313,000 |
| Operating Income | $-33,646,000 | $-44,010,000 | $-81,940,000 | $-115,156,000 |
| Depreciation Amortization Depletion Income Statement | $10,843,000 | $10,843,000 | $10,843,000 | $550,000 |
| Depreciation And Amortization In Income Statement | $10,843,000 | $10,843,000 | $10,843,000 | $550,000 |
| Amortization Of Intangibles Income Statement | $10,843,000 | $10,843,000 | $10,843,000 | $550,000 |
| Gross Profit | $166,238,000 | $135,269,000 | $87,614,000 | $36,272,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
| Basic EPS | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $67,757 | $46,495 | $-38,829 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-15,700,000 | $-26,099,000 | $-66,694,000 | $-112,964,000 |
| Total Unusual Items | $1,706,000 | $2,364,000 | $-2,620,000 | $-702,000 |
| Total Unusual Items Excluding Goodwill | $1,706,000 | $2,364,000 | $-2,620,000 | $-702,000 |
| Reconciled Depreciation | $12,625,000 | $13,160,000 | $12,668,000 | $1,879,000 |
| EBITDA (Bullshit earnings) | $-13,994,000 | $-23,735,000 | $-69,314,000 | $-113,666,000 |
| EBIT | $-26,619,000 | $-36,895,000 | $-81,982,000 | $-115,545,000 |
| Diluted Average Shares | $146,772,758 | $137,674,857 | $135,628,721 | $79,027,062 |
| Basic Average Shares | $146,772,758 | $137,674,857 | $135,628,721 | $79,027,062 |
| Diluted NI Availto Com Stockholders | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Tax Provision | $-2,268,000 | $-1,249,000 | $-1,424,000 | $0 |
| Other Special Charges | $2,690,000 | $2,837,000 | $1,223,000 | - |
| Restructuring And Mergern Acquisition | $-4,388,000 | $-5,200,000 | $3,157,000 | $0 |
| Gain On Sale Of Security | $8,000 | $1,000 | $1,760,000 | $-702,000 |
| Amortization | $10,843,000 | $10,843,000 | $10,843,000 | $550,000 |
| Research And Development | $25,560,000 | $22,341,000 | $20,966,000 | $25,160,000 |
| Selling General And Administration | $163,481,000 | $146,095,000 | $137,745,000 | $125,718,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-151,395,000 | $-139,405,000 | $-98,279,000 | $-59,078,000 |
| Total Assets | $323,060,000 | $322,602,000 | $344,522,000 | $304,361,000 |
| Total Non Current Assets | $155,398,000 | $166,338,000 | $157,704,000 | $161,765,000 |
| Other Non Current Assets | $5,407,000 | $4,540,000 | $4,730,000 | $829,000 |
| Goodwill And Other Intangible Assets | $121,780,000 | $132,623,000 | $143,466,000 | $154,309,000 |
| Other Intangible Assets | $98,921,000 | $109,764,000 | $120,607,000 | $131,450,000 |
| Current Assets | $167,662,000 | $156,264,000 | $186,818,000 | $142,596,000 |
| Other Current Assets | $7,451,000 | $5,778,000 | $9,287,000 | $4,589,000 |
| Inventory | $48,175,000 | $38,838,000 | $24,735,000 | $18,118,000 |
| Receivables | $40,415,000 | $39,197,000 | $30,830,000 | $17,456,000 |
| Accounts Receivable | $40,415,000 | $39,197,000 | $30,830,000 | $17,456,000 |
| Cash Cash Equivalents And Short Term Investments | $71,621,000 | $72,451,000 | $121,966,000 | $102,433,000 |
| Cash And Cash Equivalents | $71,621,000 | $67,449,000 | $121,966,000 | $67,271,000 |
| Prepaid Assets | - | - | - | $4,589,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $160,487,000 | $123,483,000 | $65,109,000 | $20,796,000 |
| Total Debt | $271,447,000 | $229,191,000 | $198,057,000 | $88,067,000 |
| Long Term Debt And Capital Lease Obligation | $250,265,000 | $225,696,000 | $196,477,000 | $88,067,000 |
| Long Term Debt | $217,006,000 | $190,932,000 | $187,075,000 | $88,067,000 |
| Current Debt And Capital Lease Obligation | $21,182,000 | $3,495,000 | $1,580,000 | - |
| Current Debt | $15,102,000 | - | - | - |
| Other Current Borrowings | $15,102,000 | - | - | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $352,675,000 | $329,384,000 | $299,335,000 | $209,130,000 |
| Total Non Current Liabilities Net Minority Interest | $252,232,000 | $234,191,000 | $225,714,000 | $130,090,000 |
| Other Non Current Liabilities | $1,967,000 | $6,227,000 | $25,719,000 | $30,198,000 |
| Non Current Deferred Liabilities | $0 | $2,268,000 | $3,518,000 | $11,825,000 |
| Non Current Deferred Taxes Liabilities | $0 | $2,268,000 | $3,518,000 | $4,942,000 |
| Current Liabilities | $100,443,000 | $95,193,000 | $73,621,000 | $79,040,000 |
| Other Current Liabilities | $1,089,000 | $20,276,000 | $2,658,000 | $1,987,000 |
| Payables And Accrued Expenses | $39,513,000 | $40,268,000 | $44,810,000 | $53,415,000 |
| Interest Payable | $2,123,000 | $1,374,000 | $4,656,000 | $1,413,000 |
| Payables | $2,290,000 | $11,565,000 | $4,606,000 | $8,924,000 |
| Accounts Payable | $2,290,000 | $11,565,000 | $4,606,000 | $8,924,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-29,615,000 | $-6,782,000 | $45,187,000 | $95,231,000 |
| Total Equity Gross Minority Interest | $-29,615,000 | $-6,782,000 | $45,187,000 | $95,231,000 |
| Stockholders Equity | $-29,615,000 | $-6,782,000 | $45,187,000 | $95,231,000 |
| Gains Losses Not Affecting Retained Earnings | $-25,000 | $-25,000 | $-23,000 | $-31,000 |
| Other Equity Adjustments | $-25,000 | $-25,000 | $-23,000 | $-31,000 |
| Retained Earnings | $-671,861,000 | $-617,025,000 | $-554,770,000 | $-460,110,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $149,429,410 | $138,130,715 | $136,273,090 | $124,873,316 |
| Share Issued | $149,429,410 | $138,130,715 | $136,273,090 | $124,873,316 |
| Tangible Book Value | $-151,395,000 | $-139,405,000 | $-98,279,000 | $-59,078,000 |
| Invested Capital | $202,493,000 | $184,150,000 | $232,262,000 | $183,298,000 |
| Working Capital | $67,219,000 | $61,071,000 | $113,197,000 | $63,556,000 |
| Capital Lease Obligations | $39,339,000 | $38,259,000 | $10,982,000 | $0 |
| Total Capitalization | $187,391,000 | $184,150,000 | $232,262,000 | $183,298,000 |
| Additional Paid In Capital | $642,256,000 | $610,254,000 | $599,966,000 | $555,359,000 |
| Capital Stock | $15,000 | $14,000 | $14,000 | $13,000 |
| Common Stock | $15,000 | $14,000 | $14,000 | $13,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $33,259,000 | $34,764,000 | $9,402,000 | $0 |
| Current Capital Lease Obligation | $6,080,000 | $3,495,000 | $1,580,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $19,577,000 | $16,956,000 | $13,400,000 | $19,638,000 |
| Current Provisions | $19,082,000 | $14,198,000 | $11,173,000 | $4,000,000 |
| Current Accrued Expenses | $37,223,000 | $28,703,000 | $40,204,000 | $44,491,000 |
| Goodwill | $22,859,000 | $22,859,000 | $22,859,000 | $22,859,000 |
| Net PPE | $28,211,000 | $29,175,000 | $9,508,000 | $6,627,000 |
| Accumulated Depreciation | $-7,263,000 | $-6,036,000 | $-5,534,000 | $-4,135,000 |
| Gross PPE | $35,474,000 | $35,211,000 | $15,042,000 | $10,762,000 |
| Leases | $6,056,000 | $5,984,000 | $5,065,000 | $5,026,000 |
| Other Properties | $4,730,000 | $4,153,000 | $3,841,000 | $3,739,000 |
| Machinery Furniture Equipment | $2,039,000 | $1,870,000 | $2,144,000 | $1,997,000 |
| Buildings And Improvements | $22,649,000 | $23,204,000 | $3,992,000 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $5,452,000 | $10,475,000 | $5,958,000 | $5,495,000 |
| Work In Process | $10,991,000 | $10,959,000 | $11,367,000 | $7,442,000 |
| Raw Materials | $31,732,000 | $17,404,000 | $7,410,000 | $5,181,000 |
| Other Short Term Investments | $0 | $5,002,000 | $0 | $35,162,000 |
| Treasury Shares Number | - | $0 | - | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-37,849,000 | $-49,286,000 | $-103,415,000 | $-96,620,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-36,981,000 | $-47,023,000 | $-102,891,000 | $-95,535,000 |
| Cash Flow From Continuing Operating Activities | $-36,981,000 | $-47,023,000 | $-102,891,000 | $-95,535,000 |
| Operating Gains Losses | $83,000 | $3,157,000 | $-301,000 | $702,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-868,000 | $-2,263,000 | $-524,000 | $-1,085,000 |
| Investing Cash Flow | $4,883,000 | $-6,004,000 | $34,461,000 | $97,964,000 |
| Cash Flow From Continuing Investing Activities | $4,883,000 | $-6,004,000 | $34,461,000 | $97,964,000 |
| Capital Expenditure Reported | $-868,000 | $-2,263,000 | $-524,000 | $-1,085,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-3,734,000 | $-1,009,000 | $-468,000 | $-534,000 |
| Issuance Of Capital Stock | $0 | $0 | $30,000,000 | $27,000,000 |
| Financing Cash Flow | $36,168,000 | $-1,613,000 | $127,473,000 | $27,247,000 |
| Cash Flow From Continuing Financing Activities | $36,168,000 | $-1,613,000 | $127,473,000 | $27,247,000 |
| Net Common Stock Issuance | $-3,734,000 | $-1,009,000 | $29,532,000 | $26,466,000 |
| Common Stock Issuance | $0 | $0 | $30,000,000 | $27,000,000 |
| Net Other Financing Charges | - | $-1,185,000 | $-4,876,000 | $-54,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-11,831,000 | $0 | $-44,233,000 | $0 |
| Issuance Of Debt | $50,000,000 | $0 | $146,214,000 | $0 |
| Interest Paid Supplemental Data | $26,948,000 | $27,686,000 | $10,859,000 | $7,294,000 |
| End Cash Position | $75,744,000 | $71,674,000 | $126,314,000 | $67,271,000 |
| Beginning Cash Position | $71,674,000 | $126,314,000 | $67,271,000 | $37,598,000 |
| Changes In Cash | $4,070,000 | $-54,640,000 | $59,043,000 | $29,676,000 |
| Proceeds From Stock Option Exercised | $1,733,000 | $581,000 | $836,000 | $835,000 |
| Common Stock Payments | $-3,734,000 | $-1,009,000 | $-468,000 | $-534,000 |
| Net Issuance Payments Of Debt | $38,169,000 | $0 | $101,981,000 | $0 |
| Net Long Term Debt Issuance | $38,169,000 | $0 | $101,981,000 | $0 |
| Long Term Debt Payments | $-11,831,000 | $0 | $-44,233,000 | $0 |
| Long Term Debt Issuance | $50,000,000 | $0 | $146,214,000 | $0 |
| Net Investment Purchase And Sale | $5,751,000 | $-3,741,000 | $34,985,000 | $60,580,000 |
| Sale Of Investment | $40,236,000 | $40,000,000 | $34,985,000 | $103,600,000 |
| Purchase Of Investment | $-34,485,000 | $-43,741,000 | $0 | $-43,020,000 |
| Change In Working Capital | $-8,820,000 | $-6,294,000 | $-35,150,000 | $11,854,000 |
| Change In Other Working Capital | $3,812,000 | $6,418,000 | $9,680,000 | $-77,000 |
| Change In Other Current Liabilities | $1,080,000 | $818,000 | $-6,179,000 | $0 |
| Change In Payables And Accrued Expense | $-2,039,000 | $6,435,000 | $-13,925,000 | $22,296,000 |
| Change In Accrued Expense | $7,574,000 | $-524,000 | $-9,607,000 | $16,769,000 |
| Change In Payable | $-9,613,000 | $6,959,000 | $-4,318,000 | $5,527,000 |
| Change In Account Payable | $-9,613,000 | $6,959,000 | $-4,318,000 | $5,527,000 |
| Change In Prepaid Assets | $-1,673,000 | $3,206,000 | $-3,887,000 | $3,290,000 |
| Change In Inventory | $-8,782,000 | $-14,804,000 | $-7,465,000 | $-7,418,000 |
| Change In Receivables | $-1,218,000 | $-8,367,000 | $-13,374,000 | $-6,237,000 |
| Changes In Account Receivables | $-1,218,000 | $-8,367,000 | $-13,374,000 | $-6,237,000 |
| Other Non Cash Items | $-1,381,000 | $-2,995,000 | $3,632,000 | $961,000 |
| Stock Based Compensation | $18,363,000 | $10,716,000 | $12,160,000 | $11,381,000 |
| Amortization Of Securities | $-747,000 | $-1,263,000 | $184,000 | $413,000 |
| Deferred Tax | $-2,268,000 | $-1,249,000 | $-1,424,000 | $0 |
| Deferred Income Tax | $-2,268,000 | $-1,249,000 | $-1,424,000 | $0 |
| Depreciation Amortization Depletion | $12,625,000 | $13,160,000 | $12,668,000 | $1,879,000 |
| Depreciation And Amortization | $12,625,000 | $13,160,000 | $12,668,000 | $1,879,000 |
| Amortization Cash Flow | $10,843,000 | $10,843,000 | $10,843,000 | $550,000 |
| Amortization Of Intangibles | $10,843,000 | $10,843,000 | $10,843,000 | $550,000 |
| Depreciation | $1,782,000 | $2,317,000 | $1,825,000 | $1,329,000 |
| Gain Loss On Investment Securities | $-8,000 | $-1,000 | $-1,760,000 | $702,000 |
| Gain Loss On Sale Of PPE | $91,000 | $321,000 | $236,000 | $0 |
| Net Income From Continuing Operations | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 |
| Effect Of Exchange Rate Changes | - | $0 | $0 | $-3,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $38,469,000 |
| Sale Of Business | - | $0 | $0 | $38,469,000 |